Skip to main content
August 18, 2022

Within3 in European Pharmaceutical Manufacturer: how AI is changing the way pharma companies work

Within3 CTO, AI & Analytics Jason Smith talks to European Pharmaceutical Manufacturer about the possibilities of AI innovation in life science.
AI applications

Artificial intelligence (AI) is still a controversial topic in some quarters. Fueled by science fiction and often-exaggerated news coverage, some see AI applications s a threat to their job security or way of life. However, AI applications can potentially revolutionize the life science sector regarding efficiency, safety, and innovation – much like insights management technology. In a recent article for European Pharmaceutical Manufacturer, Jason Smith – Within3’s CTO, AI and analytics – discusses how AI is changing the way pharma companies work, addresses some of the historical reticence around AI adoption, and explores the areas where it can deliver the most value.

Handpicked related content: learn more about how sentiment analysis improves the patient experience

The purpose of AI is not to replace humans. In actual fact, it cannot. AI innovation in life science supports and enhances what trial teams and other life science teams can achieve.

Jason examines how those life science companies who embrace AI applications will unlock powerful insights they could not have accessed before, thanks to tools such as natural language processing and sentiment analysis.

The purpose of AI is to ensure important, potentially life-changing insights are not missed. This saves time for life science and healthcare professionals, and adds a degree of confidence to key decisions. For drug and device developers, the reality is that once organizations begin to uncover the benefits of AI, the efficiency of the sector as a whole can only increase.

You can read the entire European Pharmaceutical Manufacturer here.

Start a conversation – share this post on LinkedIn.

More insights, direct to your inbox.

Get our newsletter.